BACKGROUND: To limit the potential short and long-term morbidity of lymphadenectomy, sentinel lymph node biopsy has been proposed for endometrial cancer. The principle of sentinel lymph node biopsy relies on removal of a small number of lymph nodes that are the first drainage basins from a tumor and thus the most likely to harbor tumor cells. While the procedure may reduce morbidity, efficacy data are limited and little is known about how commonly the procedure is performed. OBJECTIVE: We examined the patterns and predictors of use of sentinel lymph node biopsy and outcomes of the procedure in women with endometrial cancer who underwent hysterectomy. STUDY DESIGN: We used the Perspective database to identify women with uterine cancer who underwent hysterectomy from 2011 through 2015. Billing and charge codes were used to classify women as having undergone lymphadenectomy, sentinel lymph node biopsy, or no nodal assessment. Multivariable models were used to examine clinical, demographic, and hospital characteristics with use of sentinel lymph node biopsy. Length of stay and cost were compared among the different methods of nodal assessment. RESULTS: Among 28,362 patients, 9327 (32.9%) did not undergo nodal assessment, 17,669 (62.3%) underwent lymphadenectomy, and 1366 (4.8%) underwent sentinel lymph node biopsy. Sentinel lymph node biopsy was performed in 1.3% (95% confidence interval, 1.0e1.6%) of abdominal hysterectomies, 3.4% (95% confidence interval, 2.7e4.1%) of laparoscopic hysterectomies, and 7.5% (95% confidence interval, 7.0e8.0%) of robotic-assisted hysterectomies. In a multivariable model, more recent year of surgery was associated with performance of sentinel lymph node biopsy. Compared to abdominal hysterectomy, those undergoing laparoscopic (adjusted risk ratio, 2.45; 95% confidence interval, 1.89e3.18) and robotic-assisted (adjusted risk ratio, 2.69; 95% confidence interval, 2.19e3.30) hysterectomy were more likely to undergo sentinel lymph node biopsy. Among women who underwent minimally invasive hysterectomy, length of stay and cost were lower for sentinel lymph node biopsy compared to lymphadenectomy. CONCLUSION: The use of sentinel lymph node biopsy for endometrial cancer increased from 2011 through 2015. The increased use was most notable in women who underwent a robotic-assisted hysterectomy.
Introduction
Although lymphadenectomy is commonly performed as part of the surgical treatment of endometrial cancer, the role of the procedure remains controversial. 1, 2 Node dissection provides important prognostic information, may help guide adjuvant treatment, and has been suggested in some studies to have a therapeutic effect. [1] [2] [3] [4] More recently, however, randomized trials failed to show a survival benefit for lymphadenectomy. 5, 6 Importantly, these studies also demonstrated that lymphadenectomy was associated with an increased risk of complications and called into question the value of the procedure. 5, 6 To limit the potential short-and longterm morbidity of lymphadenectomy, sentinel lymph node (SLN) biopsy has been proposed for endometrial cancer. [7] [8] [9] [10] The principle of SLN biopsy relies on removal of a small number of lymph nodes that are the first drainage basins from a tumor and thus the most likely to harbor tumor cells.
11,12 SLN biopsy has been extensively validated for a number of other solid tumors and is now in the standard of care in breast cancer, vulvar cancer, and melanoma. [13] [14] [15] Despite the potential benefits of SLN biopsy for endometrial cancer, the appropriate role of the procedure is uncertain. While some studies have examined the performance of SLN biopsy compared to lymphadenectomy, whether SLN biopsy can be used in lieu of lymphadenectomy and in which patients is unknown.
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Further, as randomized trials have been unable to demonstrate a survival benefit even with full lymphadenectomy, some have questioned why SLN biopsy would be utilized at all for apparent early-stage endometrial cancer. 5, 6 Given the limited data and uncertainty surrounding SLN biopsy for endometrial cancer, we examined the patterns and predictors of use of SLN biopsy in women with newly diagnosed endometrial cancer undergoing surgery.
Materials and Methods

Data source
We analyzed the Perspective database (Premier Inc, Charlotte, NC), an all-payer database that has been utilized to examine treatment patterns and quality of care of hospitalized patients in the United States. 16 Perspective captures data from >500 hospitals and includes demographic characteristics, medical diagnoses, and procedures as well as data on medication and device utilization. This study was deemed exempt by the Columbia University Institutional Review Board.
Patients and procedures
Women with a diagnosis of uterine cancer ( 
Covariates and outcomes
Demographic characteristics included age at the time of hysterectomy (<40, 40-49, 50-59, 60-69, 70 years), year of the surgical procedure (2011 through 2015), marital status (married, single, other/unknown), race (white, black, other/unknown), and insurance coverage (commercial, Medicare, Medicaid, uninsured, unknown). The Elixhauser comorbidity index was used to perform risk adjustment for medical comorbidities. Patients were classified as having 0, 1, or 2 comorbidities.
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Hospital characteristics examined included hospital location (urban vs rural), whether the hospital was a teaching hospital (nonteaching vs teaching), hospital bed size (<400, 400-600, >600), and region of the country in which the hospital was located (Northeastern, Midwest, South, West). Procedure volume was estimated as annualized hospital volume and calculated as the total number of hysterectomies performed by a given hospital divided by the number of quarters in which that hospital performed at least 1 operation and multiplied by 4. Annualized hospital volume was included as a continuous variable in the regression models.
Length of stay and hospital cost were analyzed. Length of stay was estimated as the number of hospital days from the time the hysterectomy was performed until discharge from the hospital. 18 Cost was captured from hospital-level costs reported by facilities. Perspective captures cost data through a log of all services, treatments, and items billed to a patient during the hospital stay. 16 Within the database, approximately three fourths of hospitals report direct cost based on procedural accounting, while the remaining 25% of hospitals estimate cost based on Medicare cost-to-charge ratios. 19, 20 The total hospital cost for the index admission in which the hysterectomy was performed was captured for each patient. The recorded cost was adjusted for inflation using the Consumer Price Index and reported in 2015 US dollars. 21 To limit the influence of extreme costs, costs estimates were winsorized to the 3rd and 97th percentiles.
Statistical analysis
Frequency distributions between categorical variables were compared using c 2 tests. The trends in use of SLN biopsy over time, stratified by mode of hysterectomy, are reported using CochranArmitage trend tests. Cost data and length of stay are reported as medians with interquartile ranges (IQR), and compared using the Kruskal-Wallis nonparametric tests.
The association between the clinical, demographic, and hospital characteristics and performance of SLN biopsy were examined using multivariate randomintercept Poisson regression models. These models include all of the reported covariates as well as a hospital-specific intercept to account for clustering at the hospital level. A sensitivity analysis was performed in which the cohort was limited to only women who underwent a minimally invasive hysterectomy (laparoscopic or robotic-assisted). A second sensitivity analysis was undertaken and included only patients who underwent surgery in 2014 through 2015. Results are reported as adjusted risk ratios (aRR) and 95% confidence intervals (CI).
Quantile (median) regression models were developed to estimate the association between SLN biopsy and cost after adjusting for other clinical and hospital characteristics. 22 This methodology directly estimates the adjusted median costs for each covariate, while 95% CI were derived based on bootstrap resampling methods. 23 Results are reported as differences in the median from the referent group and 95% CI. All analyses were performed with software (SAS, Version 9.4; SAS Institute Inc, Cary, NC). All statistical tests were 2-sided.
Results
A total of 28,362 patients treated at 463 hospitals were identified. The cohort included 9480 (33.4%) women who underwent abdominal hysterectomy, 3915 (13.8%) who underwent laparoscopic hysterectomy, and 14,967 (52.8%) who had a robotically assisted procedure (Table 1) . Overall, 9327 (32.9%) patients did not undergo lymph node assessment, 17,669 (62.3%) underwent lymphadenectomy, and 1366 (4.8%) underwent SLN biopsy. SLN biopsy was performed in 1.3% (95% CI, ajog.org Among the women who underwent SLN biopsy, 850 (62.2%) had the procedure performed using indocyanine green, 523 (38.3%) using isosulfan blue, and 133 (9.7%) with technetium-99. Use of indocyanine green (P < .0001) and isosulfan blue (P <.0001) both increased over time while technetium-99 use (P ¼ .19) remained stable ( Table 2 ). The use of SLN biopsy for women who underwent abdominal hysterectomy was 1.3% in 2011 and then increased to 1.9% in 2014 and declined slightly to 1.1% in 2015 (P ¼.09) (Figure) . For laparoscopic hysterectomy, the rate of SLN biopsy increased from 1.4% in 2011 to 6.4% in 2015 (P < .001). For robotic hysterectomy, the rate of SLN biopsy increased year after year from 1.9% in 2011 to 16 .4% in 2015 (P < .001).
In a multivariate model, more recent year of surgery was associated with performance of SLN biopsy. Compared to women operated on in 2011, the aRR for SLN biopsy for those treated in 2014 was In a model limited to women who underwent minimally invasive hysterectomy, year of surgery and increased comorbidity remained associated with SLN biopsy (Table 2 ). In this model, women treated at larger hospitals were less likely to undergo SLN biopsy. In an analysis limited to 2014 and 2015, mode of hysterectomy was the only factor associated with SLN biopsy; those women who underwent either a laparoscopic or robotic-assisted hysterectomy were more likely to undergo SLN biopsy.
Among women who underwent a laparoscopic or robotic-assisted hysterectomy, the median length of stay was 0 days (IQR 0-1) in women who underwent no nodal assessment, 1 day (IQR 0-1) in those who had a lymphadenectomy, and 0 days (IQR 0-1) in women who underwent SLN biopsy ( Table 4 ). The median hospital cost for women who underwent a minimally invasive hysterectomy without nodal assessment was $8877 (IQR $6974-11,352). In comparison, the median cost of minimally invasive hysterectomy with lymphadenectomy was $10,259 (IQR $7807-13,034) and $9550 (IQR $7278-13,124) for SLN biopsy. In an adjusted model, compared to no nodal assessment, lymphadenectomy was associated with $1418 (95% CI, $1300e1536) in increased median costs while SLN biopsy was associated with a $950 (95% CI, $697e1204) increase in median cost.
In a sensitivity analysis, a total of 1123 women had a charge code for methylene blue (Supplemental Table 1 ). If methylene blue was used for SLN biopsy in all of these women, the total rate of SLN biopsy increased to 8.5% within the cohort. In this analysis the predictors of SLN biopsy were similar to those seen in the analysis without methylene blue (Supplemental Table 2 ). Likewise, trends for length of stay and cost were similar (Supplemental Table 3 ).
Comment
We noted that, despite the unclear role of SLN biopsy in endometrial cancer, the use of the procedure increased rapidly from 2011 through 2015. The increased use of the procedure was most notable in women who underwent a robotic-assisted hysterectomy. Compared to lymphadenectomy, SLN biopsy was associated with lower hospital costs even after adjusting for the route of surgery.
To date, much of the data examining SLN biopsy for endometrial cancer focused on the identification of a SLN and on comparisons between different mapping techniques. 12 A recent systematic review that included 17 studies reported that the SLN detection rates in endometrial cancer ranged from 60-100%. 12 Reports that included >100 patients had detection rates of >80%.
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Studies that directly examined the ability of SLN biopsy to identify nodal metastases noted mixed findings.
7-10 The multicenter, prospective SENTI-ENDO study, which included 133 patients, reported a sensitivity of 84% and negative predictive value of 97% for the detection of metastatic disease. 7 A single institution study that included 498 women noted a false-negative rate for the detection of positive nodes of 15%. 8 A number of technical factors influence the accuracy of SLN biopsy for endometrial cancer. 8, 11 Given that endometrial tumors are not readily visualized prior to hysterectomy, the optimal injection site for SLN mapping remains uncertain.
11,12 While cervical injection is most commonly used, some studies also used hysteroscopic localization or injection of the uterine fundus.
11, 12 While many studies used a combination of blue dye and technetium-99, the optimal dye or combination is uncertain. 7, 11, 12 Recent studies suggested that indocyanine green may be superior to blue dyes. 24, 25 Lastly, 26, 27 However, the prognostic significance of these findings on clinical outcomes remains uncertain. 27 We noted that the route of hysterectomy was an important factor in use of SLN biopsy. In particular, those women who underwent a robotically assisted hysterectomy were more likely to have a Mixed effect models were fitted accounting for hospital-level clustering using random-intercept log-Poisson regression models. Covariates included age, year, marital status, race, insurance status, hospital location, teaching status, bed size, region, comorbidity, route of hysterectomy, and annualized hospital volume. Hospital location was not adjusted for in model limiting to 2014 through 2015 because of convergence issue.
aRR, adjusted risk ratio; CI, confidence interval. a P value <.05. 
TABLE 4
Length of stay and cost associated with lymph node assessment in women with endometrial cancer who underwent robotic-assisted or laparoscopic hysterectomy Multivariable median regression models were fitted using interior point algorithm with resampling method (1000 repeats) to compute CI, adjusted for age, year, marital status, race, insurance status, hospital location, teaching status, bed size, region, comorbidity, route of hysterectomy, annualized hospital volume, any complication, and lymph node assessment.
CI, confidence interval; IQR, interquartile range.
a Cost was adjusted for inflation using Consumer Price Index to 2015 US dollars and winsorized to 3rd and 97th percentiles.
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Original Research GYNECOLOGY ajog.org SLN procedure. Currently available robotic technology is often equipped with near infrared fluorescence imaging to allow performance of SLN biopsy with indocyanine green. 24, 28 Given that use of SLN biopsy increased much more rapidly in women undergoing roboticassisted hysterectomy, the easy access of this technology with the robotic platform may be a factor driving the diffusion of SLN biopsy. Prior work has suggested that surgeons are often influenced to use technological advances when they are readily available even in the absence of data. 29, 30 Compared to lymphadenectomy, SLN biopsy was associated with lower costs. Among women who underwent minimally invasive hysterectomy, the adjusted cost of SLN biopsy was approximately $700 lower than for lymphadenectomy. The lower cost for SLN biopsy is likely multifactorial; the currently available agents used for SLN mapping are relatively inexpensive and the time to perform a sentinel node biopsy is likely substantially less than a full lymphadenectomy. Prior studies of breast cancer also reported that the costs of SLN biopsy are lower than axillary dissection both in the short and long term. 31 While our study benefits from the inclusion of a large cohort of women, we recognize several important limitations. First, coding for SLN biopsy relies on a number of procedural and charge codes. Although this methodology has been used in other analyses, a small number of women who underwent SLN biopsy may not have been captured. 16, 32 Second, we cannot accurately distinguish those women who underwent SLN biopsy followed by lymphadenectomy and those women who only underwent sentinel node assessment. A priori the goal of our study was to examine patterns of use of SLN biopsy and not specifically examine performance characteristics. Third, our analysis was limited to acute, in-hospital outcomes. Many of the potential benefits of SLN biopsy, such as a reduced rate of lymphedema, will require long-term followup. Similarly, we were unable to examine the impact of SLN biopsy on survival, which clearly warrants further evaluation. Lastly, our data set lacks a number of important demographic factors such as body mass index, tumor characteristics such as stage and histology, and patient preferences that likely influenced the use of SLN biopsy.
While SLN biopsy may be safe, patient selection criteria for the procedure remain controversial. Many have advocated SLN biopsy for low-risk, earlystage tumors. However, among these women the risk of nodal disease is low and nodal assessment has not been shown to improve outcomes, calling into question the utility of SLN biopsy in this population. 5, 6 Alternatively, women with higher grade tumors with myometrial invasion are at greater risk for nodal metastases. For these patients, however, there is greater concern that nodal metastases may be missed given the appreciable false-negative rates of SLN biopsy in some series. Currently, the National Comprehensive Cancer Network Guidelines suggest that SLN biopsy may be considered in select patients with endometrial cancer. 33 Moving forward, randomized studies as well as prospective observational studies would be of great value to help define the role of SLN biopsy for endometrial cancer. n SUPPLEMENTAL 
